Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma
This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC).
Fifty patients with portal vein tumor thrombosis were enrolled. Of these, 21 patients were treated using subcutaneous administration of PEG-IFNα-2b and intra-arterial infusion of 5-FU (5-FU/PEG-IFN group), 12 patients were treated using intramuscular administration of IFNα-2b and intra-arterial infusion of 5-FU (5-FU/IFN group), and 17 patients received intra-arterial infusion chemotherapy with lipiodol-cisplatin (CDDP) suspension (CDDP group).
The objective early response rate was significantly higher in the 5-FU/PEG-IFN group than in the 5-FU/IFN or CDDP groups (71.4 vs. 8.3% and 17.6%, respectively; P < 0.0001). Cumulative survival rates at 6 and 12 months were 83.8 and 77.8% in the 5-FU/PEG-IFN group, 60.8 and 16.2% in the 5-FU/IFN group, and 58.4 and 12.5% in the CDDP group, respectively. The cumulative survival rate was significantly higher in the 5-FU/PEG-IFN group than in the other 2 groups (P = 0.0272). Serious complications and treatment-related deaths were not observed in any of the 3 groups.
Although a prospective randomized controlled trial using a larger population of patients with advanced HCC is needed to evaluate combination therapy with 5-FU and PEG-IFNα-2b, this new combination therapy may be useful for patients with advanced HCC.
Keywords5-Fluorouracil Hepatocellular carcinoma PEG-IFNα-2b Portal venous invasion
The authors wish to thank Ms. Kouko Motodate for preparing serum samples.
Conflict of interest
No author has any conflict of interest.
- 5.Shiina S, Tagawa K, Unuma T et al (1990) Percutaneous ethanol injection therapy for treatment of hepatocellular carcinoma. Am J Roentgenol 154:947–951Google Scholar
- 15.Liver Cancer Study Group of Japan (2000) The general rules for the clinical and pathological study of primary liver cancer, 4th edn. Kanehara, Tokyo, p 19 (in Japanese)Google Scholar
- 18.NCI Common Toxicity Criteria. Common terminology criteria for adverse events v3.0 (CTCAE). Cited 9 August 2006. Available from: http://ctep.cancer.gov/reporting/ctc.html
- 27.Drewinko B, Yang L-Y (1985) Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Res 69:1391–1398Google Scholar
- 29.Ueshima K, Tatsumi C, Sakaguchi Y et al (2006) Breakthrough of the hepatic arterial infusion chemotherapy of hepatocellular carcinoma. Gastroenterology (Tokyo) 43:253–259 (in Japanese)Google Scholar
- 32.Kantoh T, Abo H, Tomotsu K et al (1993) Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization (TAE)––significance of repetitive therapies and responses to them within 6 months after the first intervention. Nippon Shokakibyo Gakkai Zasshi 90:1416–1424 (in Japanese)PubMedGoogle Scholar